GuidelineJournal of the National Comprehensive Cancer Network : JNCCN2010
Pancreatic adenocarcinoma.
Guideline in Journal of the National Comprehensive Cancer Network : JNCCN, 2010. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 78 papers, 1 of them a synthesis that pooled it.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
78 citing papers in PubMed, 1 synthesis or guideline pooled it.
- Prognostic significance of positive peritoneal cytology in resectable pancreatic cancer: a systemic review and meta-analysis.Oncotarget · 2017Pooled it
- Final analysis of a phase II study of modified FOLFIRINOX in locally advanced and metastatic pancreatic cancer.British journal of cancer · 2016Trial
- A phase II study of the halichondrin B analog eribulin mesylate in gemcitabine refractory advanced pancreatic cancer.Investigational new drugs · 2012Trial
- Perioperative changes in systemic inflammatory markers predict major complications after distal pancreatectomy.Updates in surgery · 2026Article
- Combined Association of Time to Treatment, Guideline Concordance, and Neighborhood Vulnerability with Localized Colon Cancer, Non-small-cell Lung Cancer, and Pancreatic Cancer Survival.Annals of surgical oncology · 2026Article
- Preoperative CT and inflammatory index-based risk scores for predicting short-term recurrence following resection of pancreatic ductal adenocarcinoma.BMC surgery · 2026Article
- Learning Curve Effect in Reducing Local Recurrence Rate After Resection of Pancreatic Cancer With Arterial Abutment: A Single-Center Retrospective Study.Annals of gastroenterological surgery · 2026Article
- Resection Rates and Predictors of Resectability of Pancreatic Tumors at Mulago Hospital: A Retrospective Cross-Sectional Study.Cancer management and research · 2026Article
- Changes of CA19-9 levels and related influencing factors in patients with type 2 diabetes mellitus after antidiabetic therapy.Scientific reports · 2025Observational
- An update on pancreatic cancer imaging, staging, and use of the PACT-UK radiology template pre- and post-neoadjuvant treatment.The British journal of radiology · 2025Review
- Perioperative chemotherapy with nivolumab for HER2-negative locally advanced gastric cancer: a case series.Surgical case reports · 2024Article
- Diagnostic impact of postoperative CA19-9 dynamics on pancreatic cancer recurrence: a single-institution retrospective study.Updates in surgery · 2024Article
- Impact of neoadjuvant FOLFIRINOX over upfront resection in borderline resectable pancreatic cancer-an international, multicentre, real-world analysis.ESMO real world data and digital oncology · 2024Article
- Article
- Clinical significance of tumor markers in patients with type 2 diabetes: a retrospective observational study.Diabetology international · 2023Article
- Impact of prior biliary stenting on diagnostic performance of endoscopic ultrasound for mesenteric vascular staging in patients with head of pancreas and periampullary malignancy.BMJ open gastroenterology · 2022Article
- Metastatic pancreatic cancer: Mechanisms and detection (Review).Oncology reports · 2021Review
- The immunological impact of preoperative chemoradiotherapy on the tumor microenvironment of pancreatic cancer.Cancer science · 2021Article
- Pentraxin 3 is a stromally-derived biomarker for detection of pancreatic ductal adenocarcinoma.NPJ precision oncology · 2021Article
- Essential updates 2019/2020: Multimodal treatment of localized pancreatic adenocarcinoma: Current topics and updates in survival outcomes and prognostic factors.Annals of gastroenterological surgery · 2021Review
18 more citing papers are in PubMed but not listed here.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
25 authors.
Funding
Abstract
PubMed holds no abstract for this paper.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.